Protocol for a multicentre randomiSed controlled TRial of IntraVEnous immunoglobulin versus standard therapy for the treatment of transverse myelitis in adults and children (STRIVE)

BMJ Open

Volumn 5, Issue 5, 2015, Pages

  Absoud, M ^a   Gadian, J ^a   Hellier, J ^b   Brex, P A ^a   Ciccarelli, O ^c   Giovannoni, G ^d   Kelly, J ^b   McCrone, P ^b   Murphy, C ^b   Palace, J ^e   Pickles, A ^b   Pike, M ^e   Robertson, N ^f   Jacob, A ^g   Lim, M ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d BARTS HEALTH NHS TRUST   (United Kingdom)

^e OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^f CARDIFF UNIVERSITY   (United Kingdom)

^g WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; METHYLPREDNISOLONE;

ADULT; CHILD; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; CONVALESCENCE; COST BENEFIT ANALYSIS; HEALTH CARE QUALITY; HUMAN; METHODOLOGY; MULTICENTER STUDY; MYELITIS, TRANSVERSE; PATHOLOGY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SPINAL CORD; SPINAL CORD INJURY; TREATMENT OUTCOME;

ADULT; CHILD; CLINICAL PROTOCOLS; COST-BENEFIT ANALYSIS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; METHYLPREDNISOLONE; MYELITIS, TRANSVERSE; QUALITY OF LIFE; RECOVERY OF FUNCTION; RESEARCH DESIGN; SPINAL CORD; SPINAL CORD INJURIES; STANDARD OF CARE; TREATMENT OUTCOME;

EID: 85016650266     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/BMJOPEN-2015-008312     Document Type: Article

References (24)

1. Young J, Quinn S, Hurrell M, et al. Clinically isolated acute transverse myelitis: prognostic features and incidence. Mult scler 2009;15:1295-302.
2. Absoud M, Lim MJ, Chong WK, et al. Paediatric acquired demyelinating syndromes: incidence, clinical and magnetic resonance imaging features. Mult Scler 2013;19:76-86.
3. Kerr DA, Ayetey H. Immunopathogenesis of acute transverse myelitis. Curr Opin Neurol 2002;15:339-47.
4. Borchers AT, Gershwin ME. Transverse myelitis. Autoimmun Rev 2012;11:231-48.
5. Transverse Myelitis Consortium Working Group. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology 2002;59:499-505.
6. Jacobs A, McKeon A, Nakashima I, et al. Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. J Neurol Neurosurg Psychiatry 2013;84:922-30.
7. Marino RJ, Barros T, Biering-Sorensen F, et al. International standards for neurological classification of spinal cord injury. J Spinal Cord Med 2003;26(Suppl 1):S50-6.
8. Deiva K, Absoud M, Hemingway C, et al. Acute idiopathic transverse myelitis in children: early predictors of relapse and disability. Neurology 2015;84:341-9.
9. de Seze J, Lanctin C, Lebrun C, et al. Idiopathic acute transverse myelitis: application of the recent diagnostic criteria. Neurology 2005;65:1950-3.
10. Greenberg BM, Thomas KP, Krishnan C, et al. Idiopathic transverse myelitis: corticosteroids, plasma exchange, or cyclophosphamide. Neurology 2007;68:1614-17.
11. Frohman EM, Wingerchuk DM. Clinical practice. Transverse myelitis. N Engl J Med 2010;363:564-72.
12. Scott TF, Frohman EM, De Seze J, et al. Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2011;77:2128-34.
13. Weinshenker BG, O'Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999;46:878-86.
14. Heatwole C, Johnson N, Holloway R, et al. Plasma exchange vs. intravenous immunoglobulin for myasthenia gravis crisis: an acute hospital cost comparison study. J Clin Neuromuscul Dis 2011;13:85-94.
15. Hughes RA, Dalakas MC, Cornblath DR, et al. Clinical applications of intravenous immunoglobulins in neurology. Clin Exp Immunol 2009;158(Suppl 1):34-42.
16. Banwell B, Ghezzi A, Bar-Or A, et al. Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions. Lancet Neurol 2007;6:887-902.
17. Elsone L, Panicker J, Mutch K, et al. Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients. Mult Scler 2014;20:501-4.
18. Dalakas MC. Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases. Neurology 1998;51(6 Suppl 5):S2-8.
19. Awad A, Stuve O. Idiopathic transverse myelitis and neuromyelitis optica: clinical profiles, pathophysiology and therapeutic choices. Curr Neuropharmacol 2011;9:417-28.
20. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302.
21. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-9.
22. Sellner J, Luthi N, Schupbach WM, et al. Diagnostic workup of patients with acute transverse myelitis: spectrum of clinical presentation, neuroimaging and laboratory findings. Spinal Cord 2009;47:312-17.
23. Emsley R, Dunn G, White IR. Mediation and moderation of treatment effects in randomised controlled trials of complex interventions. Stat Methods Med Res 2010;19:237-70.
24. Little TD, Bovaird JA, Widaman KF. On the merits of orthogonalizing powered and product terms: implications for modeling interactions among latent variables. Struct Equ Modeling 2006;13:497-519.